I

Innovita Biological Technology Co Ltd
SSE:688253

Watchlist Manager
Innovita Biological Technology Co Ltd
SSE:688253
Watchlist
Price: 31.99 CNY -1.75% Market Closed
Market Cap: 4.4B CNY

Innovita Biological Technology Co Ltd
Income from Continuing Operations

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Innovita Biological Technology Co Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
I
Innovita Biological Technology Co Ltd
SSE:688253
Income from Continuing Operations
ÂĄ246.9m
CAGR 3-Years
27%
CAGR 5-Years
63%
CAGR 10-Years
N/A
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
Income from Continuing Operations
ÂĄ2.1B
CAGR 3-Years
-10%
CAGR 5-Years
1%
CAGR 10-Years
N/A
S
Shanghai Conant Optical Co Ltd
HKEX:2276
Income from Continuing Operations
ÂĄ428.3m
CAGR 3-Years
33%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Winner Medical Co Ltd
SZSE:300888
Income from Continuing Operations
ÂĄ740.7m
CAGR 3-Years
-16%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
Income from Continuing Operations
ÂĄ1.8B
CAGR 3-Years
23%
CAGR 5-Years
19%
CAGR 10-Years
22%
Intco Medical Technology Co Ltd
SZSE:300677
Income from Continuing Operations
ÂĄ1.7B
CAGR 3-Years
16%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
No Stocks Found

Innovita Biological Technology Co Ltd
Glance View

Market Cap
4.4B CNY
Industry
Health Care

Innovita Biological Technology Co., Ltd. engages in the research and development, production, and sale of point-of-care testing rapid diagnostic products. The company is headquartered in Beijing, Beijing and currently employs 439 full-time employees. The company went IPO on 2022-07-28. The firm's main products include novel coronavirus (2019-nCoV) neutralizing antibody detection kits using colloidal gold, quantum dot fluorescence immunochromatography and chemiluminescence techniques, and respiratory pathogen detection products, such as whole blood respiratory quintuple detection card, influenza virus triple detection card, virus serum quintuple detection card, respiratory pathogen nine indirect immunofluorescence kit, and others.

Intrinsic Value
25.1 CNY
Overvaluation 22%
Intrinsic Value
Price
I

See Also

What is Innovita Biological Technology Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
246.9m CNY

Based on the financial report for Dec 31, 2024, Innovita Biological Technology Co Ltd's Income from Continuing Operations amounts to 246.9m CNY.

What is Innovita Biological Technology Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
63%

Over the last year, the Income from Continuing Operations growth was 42%. The average annual Income from Continuing Operations growth rates for Innovita Biological Technology Co Ltd have been 27% over the past three years , 63% over the past five years .

Back to Top